Effect of Renal Impairment on Evobrutinib Pharmacokinetics (PK)
NCT03436394
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
31
Enrollment
INDUSTRY
Sponsor class
Conditions
Renal Impairment
Interventions
DRUG:
Evobrutinib
Sponsor
Merck KGaA, Darmstadt, Germany